Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -2.7027027027 | 1.48 | 1.57 | 1.4 | 64155 | 1.51649331 | CS |
| 4 | -0.12 | -7.69230769231 | 1.56 | 1.57 | 1.4 | 41195 | 1.49898166 | CS |
| 12 | -0.48 | -25 | 1.92 | 2.33 | 1.4 | 72591 | 1.83460831 | CS |
| 26 | 0.05 | 3.59712230216 | 1.39 | 2.33 | 1.23 | 96412 | 1.65118683 | CS |
| 52 | -0.55 | -27.6381909548 | 1.99 | 2.33 | 1.23 | 118998 | 1.60527193 | CS |
| 156 | 0.3 | 26.3157894737 | 1.14 | 4.26 | 0.91 | 107751 | 1.99071424 | CS |
| 260 | -1.36 | -48.5714285714 | 2.8 | 6.19 | 0.61 | 134993 | 2.26470072 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.